Additionally, PRL-3 genomic amplification was associated with metastatic lymph node status, leading to advanced stage and thereby poor outcomes in patients with lymph node metastasis (P = 0.021). This evidence concerns the gene PTP4A3 and metastatic malignant neoplasm in the lymph nodes.